Q4 2025 TELA Bio Inc Earnings Call Transcript
Key Points
- TELA Bio Inc (TELA) achieved a 16% full-year revenue growth in 2025, with record fourth-quarter revenues.
- The company successfully executed a significant rebuild of its commercial foundation, enhancing its US commercial organization.
- TELA Bio Inc (TELA) expanded its sales force, with 40% of reps being new hires, showing promising early performance.
- The European business showed strong performance, contributing 15% of total revenue, with rapid adoption of OviTex in the UK and the Netherlands.
- The company launched new products, such as OviTex LTR, and enrolled patients in a hiatal hernia trial, strengthening its clinical evidence base.
- TELA Bio Inc (TELA) anticipates only 8% revenue growth for 2026, lower than previous expectations, due to the extensive changes in the commercial organization.
- The company faces challenges in executing contracts and converting them into revenue, with complex hospital contracting processes affecting timing.
- There is a mix shift in the hernia product line, with increased sales of smaller-sized units impacting revenue growth.
- The company experienced a slow start in Q1 2026, partly due to weather disruptions and the restructuring of sales territories.
- TELA Bio Inc (TELA) reported a net loss of $38.8 million for the full year 2025, slightly higher than the previous year's loss.
Good afternoon, ladies and gentlemen, and welcome to the TELA Bio fourth-quarter and full year 2025 earnings conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the conference call over to Louisa Smith from Investor Relations.
Thank you, Jonathan, and good afternoon, everyone.
Earlier today, TELA Bio released financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is available on the company's website. Joining me on today's call are Tony Koblish, Chief Executive Officer; Jeff Blizard, President; Roberto Cuca, Chief Operating Officer and Chief Financial Officer; and Jim Hagen, Senior Vice President of Strategic Operations and Marketing.
Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
